Toronto, Ontario–(Newsfile Corp. – April 27, 2021) – Awakn Life Sciences Inc. (Awakn), a biotechnology company with clinical operations researching, developing, and delivering psychedelic medicines to treat Addiction, announced today the initiation of a new chemical entity (NCE) development program to strengthen Awakn’s pipeline for the treatment of a broad range of addictions.


Previous articlePT241 – Nick Meyers and Tyler Chandler of “Dosed”: Iboga and The Opioid Crisis
Next articleLobe Sciences Enters into Joint Venture with Virtual Psychedelics Incorporated to Develop Multi-Sensory Pods for Clinical Psychedelic Use